Medicare Enrolled
Dr. Richard Furie, M.D.
Rheumatology · New Hyde Park, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Furie from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Furie?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Furie
Dr. Richard Furie is a rheumatology specialist in New Hyde Park, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Furie performed 150,965 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Furie received a total of $672,007 from 43 pharmaceutical and/or device companies across 496 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Furie is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 1% volume in NY
$672,007 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗150,965
Medicare services
Top 1% in NY for rheumatology
Not available
Unique patients (not deduplicated)
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, belatacept, 1 mg | 72,700 | $3 | $12 |
| Vedolizumab infusion (Entyvio) This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams. |
44,100 | $17 | $66 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
16,535 | $26 | $258 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
13,700 | $36 | $141 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
765 | $62 | $391 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
755 | $6 | $83 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
538 | $19 | $121 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
370 | $8 | $37 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
361 | $27 | $214 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
352 | $126 | $955 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
263 | $35 | $309 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
209 | $107 | $689 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
106 | $13 | $115 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
42 | $76 | $494 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
41 | $36 | $107 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
36 | $4 | $21 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
35 | $161 | $979 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
29 | $72 | $210 |
| Pneumonia vaccine administration This procedure involves the injection of a vaccine to protect against pneumococcal disease. It is administered by a healthcare provider. |
16 | $34 | $107 |
| Quadrivalent influenza vaccine, preservative-free A flu shot containing four strains of the influenza virus, formulated without preservatives, administered in a 0.5 ml dose. |
12 | $22 | $65 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
50.3% high complexity
49.2% medium
0.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$672,007
Total received (2018-2024)
Avg $96,001/year across 7 years
Top 2% in NY for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
43
Companies
496
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$116,540
2023
$87,926
2022
$127,111
2021
$66,443
2020
$76,594
2019
$118,348
2018
$79,045
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$40,479
AstraZeneca UK Limited
$24,211
E.R. Squibb & Sons, L.L.C.
$12,732
Alexion Pharmaceuticals, Inc.
$8,188
Merck Sharp & Dohme LLC
$7,712
Takeda Pharmaceuticals U.S.A., Inc.
$5,400
GlaxoSmithKline, LLC.
$3,751
Otsuka Pharmaceutical Development & Commercialization, Inc.
$2,880
Novartis Pharmaceuticals Corporation
$2,400
Kyowa Kirin Co., Ltd
$2,350
Regeneron Pharmaceuticals, Inc.
$1,822
Genentech, Inc.
$1,150
F. Hoffmann-La Roche AG
$1,150
VERTEX PHARMACEUTICALS INCORPORATED
$1,050
Janssen Research & Development, LLC
$580
ABBVIE INC.
$500
Janssen Biotech, Inc.
$115
SUN PHARMACEUTICAL INDUSTRIES INC.
$46
Celgene Corporation
$24
Top 3 companies account for 66.4% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$194,975
AstraZeneca UK Limited
$85,122
E.R. Squibb & Sons, L.L.C.
$61,208
GlaxoSmithKline, LLC.
$46,306
Eli Lilly and Company
$41,173
Alexion Pharmaceuticals, Inc.
$25,840
Genentech, Inc.
$25,586
Biogen, Inc.
$23,400
SANOFI-AVENTIS U.S. LLC
$22,425
EMD Serono, Inc.
$20,436
Celgene Corporation
$16,684
UCB SA
$11,588
Merck Sharp & Dohme LLC
$10,037
SANOFI US SERVICES INC.
$9,998
F. Hoffmann-La Roche AG
$7,479
UCB GmBH
$7,305
Boehringer Ingelheim International GmbH
$5,987
Otsuka Pharmaceutical Development & Commercialization, Inc.
$5,918
Amgen Inc.
$5,773
Takeda Pharmaceuticals U.S.A., Inc.
$5,400
Novartis Pharma AG
$4,680
Daiichi Sankyo Inc.
$3,405
Roche Products Limited
$3,250
Kyowa Kirin Co., Ltd
$2,850
Aurinia Pharma U.S., Inc.
$2,494
Janssen Research & Development, LLC
$2,480
Novartis Pharmaceuticals Corporation
$2,400
Janssen Global Services, LLC
$2,107
Merck Sharp & Dohme Corporation
$1,875
Regeneron Pharmaceuticals, Inc.
$1,822
AbbVie, Inc.
$1,757
Gilead Sciences, Inc.
$1,750
ABBVIE INC.
$1,500
ARGENX US, INC.
$1,500
Vertex Pharmaceuticals Incorporated
$1,433
AstraZeneca AB
$1,395
VERTEX PHARMACEUTICALS INCORPORATED
$1,050
Horizon Therapeutics plc
$500
Kyowa Hakko Kirin Co., Ltd
$500
Celltrion Healthcare Co., Ltd
$450
Janssen Biotech, Inc.
$115
SUN PHARMACEUTICAL INDUSTRIES INC.
$46
Lilly USA, LLC
$10
Top 3 companies account for 50.8% of all-time payments
Associated products mentioned in payments ›
Atacicept · BENLYSTA · CFZ533X · FASENRA · GAZYVA · Gazyva · INFLECTRA · KRYSTEXXA · LUPKYNIS · NO PRODUCT DISCUSSED · NUCALA · Non-Covered Product · ORENCIA · Ozanimod · RINVOQ · SAPHNELO · TALTZ · TAVNEOS · TREMFYA · Tavneos · ULTOMIRIS · Ultomiris · VYVGART
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Rheumatologists in nearby ZIP areas
354
County median income
$143,408
Nearest hospital to ZIP centroid (approximate)
LONG ISLAND JEWISH MEDICAL CENTER
1.3 mi
1.3 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Furie is a mixed practice specialist, with above-average Medicare volume (top 1% in NY), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Furie experienced with injection, belatacept, 1 mg?
Based on Medicare claims data, Dr. Furie performed 72,700 injection, belatacept, 1 mg services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Furie receive payments from pharmaceutical companies?
Yes. Dr. Furie received a total of $672,007 from 43 companies across 496 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Furie's costs compare to other rheumatologists in New Hyde Park?
Dr. Furie's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Furie) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in New Hyde Park
Browse rheumatologists in New Hyde Park ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in NY
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in NY
Which NY rheumatologists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
AstraZeneca UK Limited Payments to Doctors
See all physicians who received payments from AstraZeneca UK Limited.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology